S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Important info on NVDA trade (Ad)
2 stocks that faded their price gaps after crushing earnings
Give up the OPEC fight with these 3 stocks, Buffett-certified
Important info on NVDA trade (Ad)
10-year yield is below 4.5%...these dividend growth yields aren’t
AI revolution: 3 stocks set to soar as technology evolves
Important info on NVDA trade (Ad)
Is there money hiding under these 2 mattress stocks?
3 reasons a squeeze could be in Paramount's coming attractions
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Important info on NVDA trade (Ad)
2 stocks that faded their price gaps after crushing earnings
Give up the OPEC fight with these 3 stocks, Buffett-certified
Important info on NVDA trade (Ad)
10-year yield is below 4.5%...these dividend growth yields aren’t
AI revolution: 3 stocks set to soar as technology evolves
Important info on NVDA trade (Ad)
Is there money hiding under these 2 mattress stocks?
3 reasons a squeeze could be in Paramount's coming attractions
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Important info on NVDA trade (Ad)
2 stocks that faded their price gaps after crushing earnings
Give up the OPEC fight with these 3 stocks, Buffett-certified
Important info on NVDA trade (Ad)
10-year yield is below 4.5%...these dividend growth yields aren’t
AI revolution: 3 stocks set to soar as technology evolves
Important info on NVDA trade (Ad)
Is there money hiding under these 2 mattress stocks?
3 reasons a squeeze could be in Paramount's coming attractions
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Important info on NVDA trade (Ad)
2 stocks that faded their price gaps after crushing earnings
Give up the OPEC fight with these 3 stocks, Buffett-certified
Important info on NVDA trade (Ad)
10-year yield is below 4.5%...these dividend growth yields aren’t
AI revolution: 3 stocks set to soar as technology evolves
Important info on NVDA trade (Ad)
Is there money hiding under these 2 mattress stocks?
3 reasons a squeeze could be in Paramount's coming attractions

Envista Stock Price, News & Analysis (NYSE:NVST)

$23.89
-0.21 (-0.87%)
(As of 11/27/2023 ET)
Compare
Today's Range
$23.75
$24.09
50-Day Range
$21.06
$28.62
52-Week Range
$20.00
$43.29
Volume
1.22 million shs
Average Volume
2.78 million shs
Market Capitalization
$4.09 billion
P/E Ratio
22.12
Dividend Yield
N/A
Price Target
$34.63

Envista MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
44.9% Upside
$34.63 Price Target
Short Interest
Healthy
4.45% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.58
Upright™ Environmental Score
News Sentiment
0.34mentions of Envista in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$417,125 Bought Last Quarter
Proj. Earnings Growth
5.56%
From $1.62 to $1.71 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.87 out of 5 stars

Medical Sector

27th out of 935 stocks

Dental Equipment & Supplies Industry

1st out of 3 stocks


NVST stock logo

About Envista Stock (NYSE:NVST)

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists, and periodontists; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant for treatment planning of dental implants; DTX Studio Lab for prosthetics treatment planning; and DTX Studio Clinic, a software package offered with its imaging devices. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related consumables; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, Gendex, i-CAT, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

NVST Stock Price History

NVST Stock News Headlines

Important info on NVDA trade
Today, I’m pulling back the curtain on my all-new Everyday Income project. A way for everyday folks to target a couple hundred bucks or more every single day the markets are open… Without breaking a sweat!
7 Analysts Have This to Say About Envista Holdings
Envista Announces Release of 2022 Sustainability Report
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
3 Stocks Primed to Get a Post-Halloween Lift
Envista: Q3 Earnings Snapshot
Envista Reports Third Quarter 2023 Earnings
Earnings Preview: Envista Holdings
See More Headlines
Receive NVST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Envista and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
11/27/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/14/2024

Industry, Sector and Symbol

Industry
Dental equipment & supplies
Sub-Industry
N/A
Sector
Medical
Employees
12,700
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$34.63
High Stock Price Target
$45.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+44.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$243.10 million
Pretax Margin
9.13%

Debt

Sales & Book Value

Annual Sales
$2.57 billion
Cash Flow
$3.11 per share
Book Value
$25.80 per share

Miscellaneous

Free Float
169,345,000
Market Cap
$4.09 billion
Optionable
Optionable
Beta
1.47
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report














NVST Stock Analysis - Frequently Asked Questions

Should I buy or sell Envista stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Envista in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NVST shares.
View NVST analyst ratings
or view top-rated stocks.

What is Envista's stock price target for 2024?

7 brokerages have issued 12 month price targets for Envista's shares. Their NVST share price targets range from $25.00 to $45.00. On average, they anticipate the company's stock price to reach $34.63 in the next twelve months. This suggests a possible upside of 44.9% from the stock's current price.
View analysts price targets for NVST
or view top-rated stocks among Wall Street analysts.

How have NVST shares performed in 2023?

Envista's stock was trading at $33.67 at the beginning of the year. Since then, NVST stock has decreased by 29.0% and is now trading at $23.89.
View the best growth stocks for 2023 here
.

Are investors shorting Envista?

Envista saw a increase in short interest in October. As of October 31st, there was short interest totaling 7,630,000 shares, an increase of 30.7% from the October 15th total of 5,840,000 shares. Based on an average daily volume of 2,180,000 shares, the days-to-cover ratio is presently 3.5 days.
View Envista's Short Interest
.

When is Envista's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 14th 2024.
View our NVST earnings forecast
.

How were Envista's earnings last quarter?

Envista Holdings Co. (NYSE:NVST) posted its earnings results on Wednesday, November, 1st. The company reported $0.43 EPS for the quarter, missing analysts' consensus estimates of $0.46 by $0.03. The firm earned $631.30 million during the quarter, compared to analysts' expectations of $647.94 million. Envista had a trailing twelve-month return on equity of 7.29% and a net margin of 7.39%. Envista's revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.47 EPS.

What is Amir Aghdaei's approval rating as Envista's CEO?

9 employees have rated Envista Chief Executive Officer Amir Aghdaei on Glassdoor.com. Amir Aghdaei has an approval rating of 21% among the company's employees. This puts Amir Aghdaei in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did Envista IPO?

(NVST) raised $603 million in an initial public offering on Wednesday, September 18th 2019. The company issued 26,800,000 shares at $21.00-$24.00 per share. J.P. Morgan, Goldman Sachs and Morgan Stanley acted as the underwriters for the IPO and Baird, Evercore ISI, Jefferies, BofA Merrill Lynch, Credit Suisse, Stifel and William Blair were co-managers.

Who are Envista's major shareholders?

Envista's stock is owned by a number of institutional and retail investors. Top institutional investors include Lazard Asset Management LLC (4.41%), Massachusetts Financial Services Co. MA (4.04%), Gates Capital Management Inc. (3.30%), Ariel Investments LLC (3.11%), Charles Schwab Investment Management Inc. (1.13%) and Montrusco Bolton Investments Inc. (1.11%). Insiders that own company stock include Amir Aghdaei, Curt W Bludworth, Curt W Bludworth, Eric Conley, Howard H Yu, Jeffrey Kappler, Mark E Nance, Mark E Nance, Mischa Reis and Stephen Keller.
View institutional ownership trends
.

How do I buy shares of Envista?

Shares of NVST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:NVST) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -